rich 1.0 Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this Mind Moments episode, Pezhman Roohani, MD, neurologist and medical director of the teleneurology and telestroke program at Allina Health, joins the podcast to discuss the emerging role of GLP-1 receptor agonists across neurology. Roohani outlines where these therapies may have the greatest impact, highlighting stroke prevention, neurodegenerative diseases, idiopathic intracranial hypertension, and other areas being explored as researchers look beyond their established metabolic effects. The conversation also examines what recent Alzheimer disease trial results mean for the future of GLP-1 research, including the potential importance of prevention and identifying patient subgroups most likely to benefit. Roohani discusses key cautions surrounding long-term use, muscle loss, nutrition, and lifestyle modification, as well as practical considerations when counseling patients. He closes by highlighting unanswered research questions and potential applications in neuroinflammation, traumatic brain injury, and addiction. Looking for more Stroke discussion? Check out the NeurologyLive® Stroke clinical focus page (https://www.neurologylive.com/clinical/ms) . Episode Breakdown: 1:15 – Neurologic conditions showing the greatest promise for GLP-1 therapies 4:15 – GLP-1s in neurodegeneration following recent Alzheimer trial results 7:35 – Key cautions and limitations surrounding long-term GLP-1 use 9:35 – Neurology News Minute 11:50– Counseling patients on lifestyle changes when initiating GLP-1 therapy 14:20 – Research priorities and emerging neurologic applications for GLP-1s The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: First-Ever Platform Trial for Progressive Supranuclear Palsy Enrolls Its Inaugural Participant (https://www.neurologylive.com/view/first-ever-platform-trial-progressive-supranuclear-palsy-enrolls-inaugural-participant) FDA Approves Tau PET Tracer MK-6240 for Alzheimer Diagnostic Workup (https://www.neurologylive.com/view/fda-approves-tau-pet-tracer-mk-6240-alzheimer-diagnostic-workup) Efgartigimod Meets Primary Endpoint in Phase 3 ALKIVIA Trial of Autoimmune Myositis (https://www.neurologylive.com/view/efgartigimod-meets-primary-endpoint-phase-3-alkivia-trial-autoimmune-myositis) Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com (http://neurologylive.com/) . NeurologyLive® Mind Moments® https://audioboom.com/channels/5001429-neurologylive-mind-moments Audioboom https://audioboom.com 480 95 https://audioboom.com/i/39490422/600x600/c 600 600 <iframe width="100%" height="95" src="https://embeds.audioboom.com/posts/8942528/embed?v=202301" style="background-color: transparent; display: block; padding: 0; width: 100%" frameborder="0" allowtransparency="allowtransparency" scrolling="no" title="Audioboom player" allow="autoplay" sandbox="allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>